1. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK (1996) The progression from hypertension to congestive heart failure. JAMA 275:1557–1562
2. Kane GC, Karon BL, Mahoney DW, Redfeld MM, Roger VL, Burnett JC Jr, Jacobsen SJ, Rodehefer RJ (2011) Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA 306:856–863
3. Abhayaratna WP, Marwick TH, Smith WT, Becker NG (2006) Characteristics of left ventricular diastolic dysfunction in the community: an echocardiographic survey. Heart 92:1259–1264
4. Kannel WB, Hjortland M, Castelli WP (1974) Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34:29–34
5. Zhong J, Maiseyeu A, Davis SN, Rajagopalan S (2015) DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. Circ Res 116:1491–1504
6. Shigeta T, Aoyama M, Bando YK, Monji A, Mitsui T, Takatsu M, Cheng XW, Okumura T, Hirashiki A, Nagata K, Murohara T (2012) Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions. Circulation 126:1838–1851
7. Takahashi A, Asakura M, Ito S, Min KD, Shindo K, Yan Y, Liao Y, Yamazaki S, Sanada S, Asano Y, Ishibashi-Ueda H, Takashima S, Minamino T, Asanuma H, Mochizuki N, Kitakaze M (2013) Dipeptidyl-peptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice. Am J Physiol Heart Circ Physiol 304:H1361-1369
8. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL, Committee S-TS, Investigators* (2014) Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 130:1579–1588
9. Nogueira KC, Furtado M, Fukui RT, Correia MR, Dos Santos RF, Andrade JL, Rossi da Silva ME (2014) Left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor—a pilot study. Diabetol Metab Syndr 6:103
10. McMurray JJV, Ponikowski P, Bolli GB, Lukashevich V, Kozlovski P, Kothny W, Lewsey JD, Krum H (2018) Efects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial. JACC Heart Fail 6:8–17
11. Witteles RM, Keu KV, Quon A, Tavana H, Fowler MB (2012) Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy. J Card Fail 18:804–809
12. Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP (2010) DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging 3:195–201
13. Fisher FM, Maratos-Flier E (2016) Understanding the physiology of FGF21. Annu Rev Physiol 78:223–241
14. Aini K, Fukuda D, Tanaka K, Higashikuni Y, Hirata Y, Yagi S, Kusunose K, Yamada H, Soeki T, Sata M (2019) Vildagliptin, a DPP-4 inhibitor, attenuates endothelial dysfunction and atherogenesis in nondiabetic apolipoprotein E-defcient mice. Int Heart J 60:1421–1429
15. Flock G, Baggio LL, Longuet C, Drucker DJ (2007) Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 56:3006–3013
16. Koitabashi N, Danner T, Zaiman AL, Pinto YM, Rowell J, Mankowski J, Zhang D, Nakamura T, Takimoto E, Kass DA (2011) Pivotal role of cardiomyocyte TGF-beta signaling in the murine pathological response to sustained pressure overload. J Clin Invest 121:2301–2312
17. Pacher P, Nagayama T, Mukhopadhyay P, Batkai S, Kass DA (2008) Measurement of cardiac function using pressure–volume conductance catheter technique in mice and rats. Nat Protoc 3:1422–1434
18. Coburn CT, Knapp FF Jr, Febbraio M, Beets AL, Silverstein RL, Abumrad NA (2000) Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice. J Biol Chem 275:32523–32529
19. Hajri T, Han XX, Bonen A, Abumrad NA (2002) Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice. J Clin Invest 109:1381–1389
20. Goto K, Iso T, Hanaoka H, Yamaguchi A, Suga T, Hattori A, Irie Y, Shinagawa Y, Matsui H, Syamsunarno MR, Matsui M, Haque A, Arai M, Kunimoto F, Yokoyama T, Endo K, Gonzalez FJ, Kurabayashi M (2013) Peroxisome proliferator-activated receptor-gamma in capillary endothelia promotes fatty acid uptake by heart during long-term fasting. J Am Heart Assoc 2:e004861
21. Nishimura T, Nakatake Y, Konishi M, Itoh N (2000) Identifcation of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 1492:203–206
22. Ryden M (2009) Fibroblast growth factor 21: an overview from a clinical perspective. Cell Mol Life Sci 66:2067–2073
23. Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, Hansen BC, Shanafelt AB, Etgen GJ (2007) The metabolic state of diabetic monkeys is regulated by fbroblast growth factor-21. Endocrinology 148:774–781
24. Sunaga H, Koitabashi N, Iso T, Matsui H, Obokata M, Kawakami R, Murakami M, Yokoyama T, Kurabayashi M (2019) Activation of cardiac AMPK-FGF21 feed-forward loop in acute myocardial infarction: role of adrenergic overdrive and lipolysis byproducts. Sci Rep 9:11841
25. Chou RH, Huang PH, Hsu CY, Chang CC, Leu HB, Huang CC, Chen JW, Lin SJ (2016) Circulating fbroblast growth factor 21 is associated with diastolic dysfunction in heart failure patients with preserved ejection fraction. Sci Rep 6:33953
26. Planavila A, Redondo I, Hondares E, Vinciguerra M, Munts C, Iglesias R, Gabrielli LA, Sitges M, Giralt M, van Bilsen M, Villarroya F (2013) Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun 4:2019
27. Di Lisa F, Itoh N (2015) Cardiac Fgf21 synthesis and release: an autocrine loop for boosting up antioxidant defenses in failing hearts. Cardiovasc Res 106:1–3
28. Salminen A, Kaarniranta K, Kauppinen A (2017) Integrated stress response stimulates FGF21 expression: systemic enhancer of longevity. Cell Signal 40:10–21
29. Han X, Chen C, Cheng G, Xie C, Yang M, Shou X, Sun C (2015) Serum fbroblast growth factor 21 levels are increased in atrial fbrillation patients. Cytokine 73:176–180
30. Markan KR, Naber MC, Ameka MK, Anderegg MD, Mangelsdorf DJ, Kliewer SA, Mohammadi M, Potthof MJ (2014) Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes 63:4057–4063
31. Mashili FL, Austin RL, Deshmukh AS, Fritz T, Caidahl K, Bergdahl K, Zierath JR, Chibalin AV, Moller DE, Kharitonenkov A, Krook A (2011) Direct efects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity. Diabetes Metab Res Rev 27:286–297
32. Jackson EK, Zhang Y, Gillespie DD, Zhu X, Cheng D, Jackson TC (2017) SDF-1α (stromal cell-derived factor 1α) induces cardiac fbroblasts, renal microvascular smooth muscle cells, and glomerular mesangial cells to proliferate, cause hypertrophy, and produce collagen. J Am Heart Assoc 6:e007253
33. Zhu X, Gillespie DG, Jackson EK (2015) NPY1-36 and PYY1-36 activate cardiac fbroblasts: an efect enhanced by genetic hypertension and inhibition of dipeptidyl peptidase 4. Am J Physiol Heart Circ Physiol 309:H1528-1542
34. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96:857–868
35. Matsushima S, Sadoshima J (2015) The role of sirtuins in cardiac disease. Am J Physiol Heart Circ Physiol 309:H1375-1389
36. Koitabashi N, Kass DA (2011) Reverse remodeling in heart failure—mechanisms and therapeutic opportunities. Nat Rev Cardiol 9:147–157
37. Tallquist MD, Molkentin JD (2017) Redefning the identity of cardiac fbroblasts. Nat Rev Cardiol 14:484–491
38. Fujiu K, Nagai R (2014) Fibroblast-mediated pathways in cardiac hypertrophy. J Mol Cell Cardiol 70:64–73
39. Araki E, Yamashita S, Arai H, Yokote K, Satoh J, Inoguchi T, Nakamura J, Maegawa H, Yoshioka N, Tanizawa Y, Watada H, Suganami H, Ishibashi S (2018) Efects of pemafbrate, a novel selective PPARalpha modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 41:538–546
40. Oka S, Alcendor R, Zhai P, Park JY, Shao D, Cho J, Yamamoto T, Tian B, Sadoshima J (2011) PPARalpha-Sirt1 complex mediates cardiac hypertrophy and failure through suppression of the ERR transcriptional pathway. Cell Metab 14:598–611
41. Gao P, Li L, Wei X, Wang M, Hong Y, Wu H, Shen Y, Ma T, Zhang Q, Fang X, Wang L, Yan Z, Du GH, Zheng H, Yang G, Liu D, Zhu Z (2020) Activation of transient receptor potential channel vanilloid 4 by DPP-4 (dipeptidyl peptidase-4) inhibitor vildagliptin protects against diabetic endothelial dysfunction. Hypertension 75:150–162
42. Adapala RK, Kanugula AK, Paruchuri S, Chilian WM, Thodeti CK (2020) TRPV4 deletion protects heart from myocardial infarction-induced adverse remodeling via modulation of cardiac fbroblast diferentiation. Basic Res Cardiol 115:14
43. Talukdar S, Zhou Y, Li D, Rossulek M, Dong J, Somayaji V, Weng Y, Clark R, Lanba A, Owen BM, Brenner MB, Trimmer JK, Gropp KE, Chabot JR, Erion DM, Rolph TP, Goodwin B, Calle RA (2016) A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profle in non-human primates and type 2 diabetic subjects. Cell Metab 23:427–440
44. Ahren B, Winzell MS, Wierup N, Sundler F, Burkey B, Hughes TE (2007) DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cellspecifc overexpression of human islet amyloid polypeptide. Regul Pept 143:97–103
45. Burkey BF, Li X, Bolognese L, Balkan B, Mone M, Russell M, Hughes TE, Wang PR (2005) Acute and chronic efects of the incretin enhancer vildagliptin in insulin-resistant rats. J Pharmacol Exp Ther 315:688–695
論文の公開元へ
